{"product_id":"hiv-peptide-t-p1136","title":"HIV Peptide T","description":"\u003ch2\u003eAbout the Target\u003c\/h2\u003e\u003cp\u003eHIV Peptide T (Peptide T), a synthetic octapeptide and an antiviral agent for use in HIV infection, of which mechanism of action consists of competitive inhibition of the binding of gp120 (a surface protein of HIV) to the CD4 receptor, homologous binding. The mapped biological anchor for this entry is CD4 receptor and VIP receptors (CD4, VIPR1, and VIPR2), although the description suggests that interpretation should remain at fragment, family, or pathway level. This target context is most often investigated as part of ligand-responsive signaling, where receptor occupancy can reshape downstream second-messenger output, trafficking, secretion, excitability, or transcriptional programs. In infection-oriented models, investigators often connect this biology with host-pathogen signaling, antiviral responses, and inflammatory control. This framing is especially useful when investigators want to connect a controlled ligand stimulus with rapidly changing cellular phenotypes.\u003c\/p\u003e\u003ch2\u003eResearch Context\u003c\/h2\u003e\u003cp\u003eIts competitive inhibitory mechanism is especially useful in experiments that need time-resolved pathway control and washout-based interpretation of direct versus downstream effects. In practice, dose-response design, timing, and matched control conditions are important for separating direct target engagement from delayed compensatory responses. Because more than one mapped molecular node is represented in the enrichment, pathway readouts should be interpreted with awareness that the phenotype may integrate multiple signaling inputs.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003epair peptide treatment with pathway-proximal signaling or trafficking readouts whenever possible\u003c\/li\u003e\n\u003cli\u003ecompare responses across cell states or model systems with different receptor abundance\u003c\/li\u003e\n\u003cli\u003edistinguish primary target engagement from downstream adaptation during longer incubations\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eExperimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.\u003c\/p\u003e\u003ch2\u003eFormat Considerations\u003c\/h2\u003e\u003cp\u003eThe standard product format is most useful for reproducible baseline experiments, matched comparative studies, and workflows that need a consistent reagent across assay repeats. In comparative workflows, consistency of preparation, exposure window, and matched controls is often as important as the nominal treatment itself. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.\u003c\/p\u003e","brand":"Selleck Chemicals","offers":[{"title":"5 mg","offer_id":57636819829081,"sku":"P1136-5MG","price":144.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0923\/1011\/0553\/files\/p1136-hiv-peptide-t-chemical-structure.gif?v=1774212327","url":"https:\/\/absource-diagnostics.myshopify.com\/products\/hiv-peptide-t-p1136","provider":"Absource Diagnostics","version":"1.0","type":"link"}